14160-91-9

Usage

Uses

Used in Organic Chemistry Research:
4,6-Dichloro-2-Methylpyrimidine-5-Carbaldehyde is used as a research compound for studying its synthesis, behavior, and potential applications in the field of organic chemistry.
Used in Pharmacology:
4,6-Dichloro-2-Methylpyrimidine-5-Carbaldehyde is used as a building block in the synthesis of complex molecules in pharmacology, especially where the presence of halogen atoms is required.
Used in Agrochemical Research:
4,6-Dichloro-2-Methylpyrimidine-5-Carbaldehyde is used as a building block in the synthesis of complex molecules in agrochemical research, contributing to the development of new agrochemical products.
Used as a Chemical Intermediate:
4,6-Dichloro-2-Methylpyrimidine-5-Carbaldehyde is used as an intermediate in the creation of more complex chemical compounds, facilitating the synthesis of a wide range of products in various industries.

Upstream product

• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 67242-59-5 N-methyl-N-(2-pyridyl)-formamide 
• 68-12-2 N,N-dimethyl-formamide 
• 1194-22-5 2-methyl-4,6-dihydroxypyrimidine 
• 15263-76-0 N-((4,6-dihydroxy-2-methylpyrimidin-5-yl)methylene)-N-methylmethanaminium chloride 

Downstream Products

• 1269116-63-3 5-ethoxy-N-[1-(hydroxyacetyl)piperidin-4-yl]-2,7-dimethyl-4-oxo-3-(2-oxo-2-phenylethyl)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-6-carboxamide 
• 30129-53-4 4-chloro-6-methylpyrazolo<3,4-d>pyrimidine 
• 1269116-61-1 N-[1-(hydroxyacetyl)piperidin-4-yl]-2,7-dimethyl-4-oxo-3-(2-oxo-2-phenylethyl)-5-(2,2,2-trifluoroethoxy)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-6-carboxamide 
• 1338327-18-6 4-amino-6-(4-bromophenyl)-2-methyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1338326-64-9 4-amino-6-(2'-chlorobiphenyl-4-yl)-2-methyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1338327-21-1 N-(4-bromophenyl)-N-(2-(tert-butyldimethylsilyloxy)ethyl)-4,6-dichloro-2-methylpyrimidine-5-carboxamide 
• 1338327-20-0 N-(4-bromophenyl)-4,6-dichloro-N-(2-hydroxyethyl)-2-methylpyrimidine-5-carboxamide 
• 1338327-19-7 6-(4-bromophenyl)-4-chloro-2-methyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 

Relevant academic research and scientific papers

SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula: wherein R1 to R4, L1, L2 and X are as described herein, compositions including the compounds and methods of using the compounds.

Design, synthesis, and evaluation of novel CXCR4 antagonists based on an aminoquinoline template

The chemokine receptor CXCR4 has been explored as a drug target due to its involvement in pathological conditions such as HIV infection and cancer metastasis. Here we report the structure–activity relationship study of novel CXCR4 antagonists based on an aminoquinoline template. This template is devoid of the chiral center in the classical tetrahydroquinoline (THQ) ring moiety and therefore can be easily synthesized. A number of potent CXCR4 antagonists were identified, exemplified by compound 3, which demonstrated excellent binding affinity with CXCR4 receptor (IC50 = 57 nM) and inhibited CXCL12 induced cytosolic calcium increase (IC50 = 0.24 nM). Furthermore, compound 3 potently inhibited CXLC12/CXCR4 mediated cell migration in a transwell invasion assay. The simplified synthetic approach combined with good physicochemical properties (e.g. MW 362, clogP 2.1, PSA 48, pKa 7.0 for compound 3) demonstrate the potential of this aminoquinoline template as a novel scaffold to develop CXCR4 antagonists.

PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS

The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the CXCR4 pathway.

Structure-based design of a novel series of potent, selective inhibitors of the class i phosphatidylinositol 3-kinases

A highly selective series of inhibitors of the class I phosphatidylinositol 3-kinases (PI3Ks) has been designed and synthesized. Starting from the dual PI3K/mTOR inhibitor 5, a structure-based approach was used to improve potency and selectivity, resulting in the identification of 54 as a potent inhibitor of the class I PI3Ks with excellent selectivity over mTOR, related phosphatidylinositol kinases, and a broad panel of protein kinases. Compound 54 demonstrated a robust PD-PK relationship inhibiting the PI3K/Akt pathway in vivo in a mouse model, and it potently inhibited tumor growth in a U-87 MG xenograft model with an activated PI3K/Akt pathway.

FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.

4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity wherein, R1, R2, R3, R4, X2, q, Y1, Y2, n, Q and Z are as defined in the description.